Global Cancer Profiling Market

Cancer Profiling Comprehensive Study by Type (Breast Cancer, Lung Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Others (Melanoma, Colorectal, Bladder, Leukemia)), Application (Clinical, Screening, Research), Treatment (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Hormone Therapy, Stem Cell Transplant, Precision Medicine), Technology (Next-Generation Sequencing (NGS), Sanger Sequencing, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Others), Technique (Genomics, Proteomics, Epigenetics, Metabolomics) Players and Region - Global Market Outlook to 2028

Cancer Profiling Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Cancer Profiling Market Scope?
Cancer profiling is done to get genetic information regarding the tumor cells which offer useful insights and information regarding the disease. Cancer profiling helps in the selection of suitable therapy for the treatment of cancer. Cancer profiling provides more precise and accurate information about the clinical outcomes of cancer. The technique plays an important role in the diagnosis of cancer at the molecular level. Cancer profiling may increase the likelihood that a patient will benefit from cancer therapy.

Influencing Trend:
Growing Utility of Biomarkers in Cancer Profiling and Rise in Number of Cancer Cases

Market Growth Drivers:
Increase in the Demand for Next Generation Sequencing Techniques in Cancer Profiling, Rise in the Adoption of the Cancer Profiling Methods by Oncologists and Growing Need for Point-Of-Care Diagnostic Tests

Challenges:
Targeting Cancer Stem Cells (CSCs) is Difficult and Problems Associated with Cancer Diagnosis

Restraints:
High Capital Investments and Lack of Skilled Professionals

Opportunities:
Availability of Funding for Cancer Research and Increasing Demand for Personalized Medicine

The Cancer Profiling market study is being classified by Type (Breast Cancer, Lung Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer and Others [Melanoma, Colorectal, Bladder, Leukemia]), by Application and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail competitive advantage through combined collaborations. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Cancer Profiling market throughout the predicted period.

Qiagen (Germany), Neogenomics Laboratories Inc. (United States), HTG Molecular Diagnostics Inc. (United States), Perthera, Inc. (United States), Strand Genomics (India), Contextual Genomics (Canada), QIAGEN N.V. (Germany), Boreal Genomics (United States), Oxford Gene Technology Ltd (United Kingdom), GenomeDx (Canada) and Foundation Medicine Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Helomics Corp (United States), Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland) and NanoString Technologies Inc. (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Cancer Profiling market by Type, Application and Region.

On the basis of geography, the market of Cancer Profiling has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies
March 08, 2019: QIAGEN N.V. and Tecan Group AG, a global leader in laboratory automation and liquid handling technology, announced a collaboration to improve the processing of QIAGEN’s QuantiFERON-TB Gold Plus (QFT-Plus) diagnostic test through the utilization of Tecan’s Fluent Laboratory Automation.
March 11, 2019: NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announce availability of the Ventana PD-L1 (SP142) Assay for tumor tissue from patients with the triple negative subtype of breast cancer.


Key Target Audience
Companies Offering Platforms for Cancer Diagnosis, Healthcare Industry, Research Institutes and Government Bodies

Cancer Profiling Market Study: Important Years
AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Cancer Profiling Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Cancer Profiling industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Kidney Cancer
  • Others [Melanoma, Colorectal, Bladder, Leukemia]
By Application
  • Clinical
  • Screening
  • Research
By Treatment
  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Hormone Therapy
  • Stem Cell Transplant
  • Precision Medicine

By Technology
  • Next-Generation Sequencing (NGS)
  • Sanger Sequencing
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Microarray
  • Others

By Technique
  • Genomics
  • Proteomics
  • Epigenetics
  • Metabolomics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Demand for Next Generation Sequencing Techniques in Cancer Profiling
      • 3.2.2. Rise in the Adoption of the Cancer Profiling Methods by Oncologists
      • 3.2.3. Growing Need for Point-Of-Care Diagnostic Tests
    • 3.3. Market Challenges
      • 3.3.1. Targeting Cancer Stem Cells (CSCs) is Difficult
      • 3.3.2. Problems Associated with Cancer Diagnosis
    • 3.4. Market Trends
      • 3.4.1. Growing Utility of Biomarkers in Cancer Profiling
      • 3.4.2. Rise in Number of Cancer Cases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Profiling, by Type, Application, Treatment, Technology, Technique and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer Profiling (Value)
      • 5.2.1. Global Cancer Profiling by: Type (Value)
        • 5.2.1.1. Breast Cancer
        • 5.2.1.2. Lung Cancer
        • 5.2.1.3. Prostate Cancer
        • 5.2.1.4. Thyroid Cancer
        • 5.2.1.5. Kidney Cancer
        • 5.2.1.6. Others [Melanoma, Colorectal, Bladder, Leukemia]
      • 5.2.2. Global Cancer Profiling by: Application (Value)
        • 5.2.2.1. Clinical
        • 5.2.2.2. Screening
        • 5.2.2.3. Research
      • 5.2.3. Global Cancer Profiling by: Treatment (Value)
        • 5.2.3.1. Surgery
        • 5.2.3.2. Radiation Therapy
        • 5.2.3.3. Chemotherapy
        • 5.2.3.4. Immunotherapy
        • 5.2.3.5. Targeted Therapy
        • 5.2.3.6. Hormone Therapy
        • 5.2.3.7. Stem Cell Transplant
        • 5.2.3.8. Precision Medicine
      • 5.2.4. Global Cancer Profiling by: Technology (Value)
        • 5.2.4.1. Next-Generation Sequencing (NGS)
        • 5.2.4.2. Sanger Sequencing
        • 5.2.4.3. Immunohistochemistry (IHC)
        • 5.2.4.4. In Situ Hybridization (ISH)
        • 5.2.4.5. Microarray
        • 5.2.4.6. Others
      • 5.2.5. Global Cancer Profiling by: Technique (Value)
        • 5.2.5.1. Genomics
        • 5.2.5.2. Proteomics
        • 5.2.5.3. Epigenetics
        • 5.2.5.4. Metabolomics
      • 5.2.6. Global Cancer Profiling Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Cancer Profiling (Price)
      • 5.3.1. Global Cancer Profiling by: Type (Price)
  • 6. Cancer Profiling: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Qiagen (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Neogenomics Laboratories Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. HTG Molecular Diagnostics Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Perthera, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Strand Genomics (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Contextual Genomics (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. QIAGEN N.V. (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Boreal Genomics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Oxford Gene Technology Ltd (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GenomeDx (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Foundation Medicine Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Cancer Profiling Sale, by Type, Application, Treatment, Technology, Technique and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer Profiling (Value)
      • 7.2.1. Global Cancer Profiling by: Type (Value)
        • 7.2.1.1. Breast Cancer
        • 7.2.1.2. Lung Cancer
        • 7.2.1.3. Prostate Cancer
        • 7.2.1.4. Thyroid Cancer
        • 7.2.1.5. Kidney Cancer
        • 7.2.1.6. Others [Melanoma, Colorectal, Bladder, Leukemia]
      • 7.2.2. Global Cancer Profiling by: Application (Value)
        • 7.2.2.1. Clinical
        • 7.2.2.2. Screening
        • 7.2.2.3. Research
      • 7.2.3. Global Cancer Profiling by: Treatment (Value)
        • 7.2.3.1. Surgery
        • 7.2.3.2. Radiation Therapy
        • 7.2.3.3. Chemotherapy
        • 7.2.3.4. Immunotherapy
        • 7.2.3.5. Targeted Therapy
        • 7.2.3.6. Hormone Therapy
        • 7.2.3.7. Stem Cell Transplant
        • 7.2.3.8. Precision Medicine
      • 7.2.4. Global Cancer Profiling by: Technology (Value)
        • 7.2.4.1. Next-Generation Sequencing (NGS)
        • 7.2.4.2. Sanger Sequencing
        • 7.2.4.3. Immunohistochemistry (IHC)
        • 7.2.4.4. In Situ Hybridization (ISH)
        • 7.2.4.5. Microarray
        • 7.2.4.6. Others
      • 7.2.5. Global Cancer Profiling by: Technique (Value)
        • 7.2.5.1. Genomics
        • 7.2.5.2. Proteomics
        • 7.2.5.3. Epigenetics
        • 7.2.5.4. Metabolomics
      • 7.2.6. Global Cancer Profiling Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Cancer Profiling (Price)
      • 7.3.1. Global Cancer Profiling by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Profiling: by Type(USD Million)
  • Table 2. Cancer Profiling Breast Cancer , by Region USD Million (2017-2022)
  • Table 3. Cancer Profiling Lung Cancer , by Region USD Million (2017-2022)
  • Table 4. Cancer Profiling Prostate Cancer , by Region USD Million (2017-2022)
  • Table 5. Cancer Profiling Thyroid Cancer , by Region USD Million (2017-2022)
  • Table 6. Cancer Profiling Kidney Cancer , by Region USD Million (2017-2022)
  • Table 7. Cancer Profiling Others [Melanoma, Colorectal, Bladder, Leukemia] , by Region USD Million (2017-2022)
  • Table 8. Cancer Profiling: by Application(USD Million)
  • Table 9. Cancer Profiling Clinical , by Region USD Million (2017-2022)
  • Table 10. Cancer Profiling Screening , by Region USD Million (2017-2022)
  • Table 11. Cancer Profiling Research , by Region USD Million (2017-2022)
  • Table 12. Cancer Profiling: by Treatment(USD Million)
  • Table 13. Cancer Profiling Surgery , by Region USD Million (2017-2022)
  • Table 14. Cancer Profiling Radiation Therapy , by Region USD Million (2017-2022)
  • Table 15. Cancer Profiling Chemotherapy , by Region USD Million (2017-2022)
  • Table 16. Cancer Profiling Immunotherapy , by Region USD Million (2017-2022)
  • Table 17. Cancer Profiling Targeted Therapy , by Region USD Million (2017-2022)
  • Table 18. Cancer Profiling Hormone Therapy , by Region USD Million (2017-2022)
  • Table 19. Cancer Profiling Stem Cell Transplant , by Region USD Million (2017-2022)
  • Table 20. Cancer Profiling Precision Medicine , by Region USD Million (2017-2022)
  • Table 21. Cancer Profiling: by Technology(USD Million)
  • Table 22. Cancer Profiling Next-Generation Sequencing (NGS) , by Region USD Million (2017-2022)
  • Table 23. Cancer Profiling Sanger Sequencing , by Region USD Million (2017-2022)
  • Table 24. Cancer Profiling Immunohistochemistry (IHC) , by Region USD Million (2017-2022)
  • Table 25. Cancer Profiling In Situ Hybridization (ISH) , by Region USD Million (2017-2022)
  • Table 26. Cancer Profiling Microarray , by Region USD Million (2017-2022)
  • Table 27. Cancer Profiling Others , by Region USD Million (2017-2022)
  • Table 28. Cancer Profiling: by Technique(USD Million)
  • Table 29. Cancer Profiling Genomics , by Region USD Million (2017-2022)
  • Table 30. Cancer Profiling Proteomics , by Region USD Million (2017-2022)
  • Table 31. Cancer Profiling Epigenetics , by Region USD Million (2017-2022)
  • Table 32. Cancer Profiling Metabolomics , by Region USD Million (2017-2022)
  • Table 33. South America Cancer Profiling, by Country USD Million (2017-2022)
  • Table 34. South America Cancer Profiling, by Type USD Million (2017-2022)
  • Table 35. South America Cancer Profiling, by Application USD Million (2017-2022)
  • Table 36. South America Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 37. South America Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 38. South America Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 39. Brazil Cancer Profiling, by Type USD Million (2017-2022)
  • Table 40. Brazil Cancer Profiling, by Application USD Million (2017-2022)
  • Table 41. Brazil Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 42. Brazil Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 43. Brazil Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 44. Argentina Cancer Profiling, by Type USD Million (2017-2022)
  • Table 45. Argentina Cancer Profiling, by Application USD Million (2017-2022)
  • Table 46. Argentina Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 47. Argentina Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 48. Argentina Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 49. Rest of South America Cancer Profiling, by Type USD Million (2017-2022)
  • Table 50. Rest of South America Cancer Profiling, by Application USD Million (2017-2022)
  • Table 51. Rest of South America Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 52. Rest of South America Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 53. Rest of South America Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 54. Asia Pacific Cancer Profiling, by Country USD Million (2017-2022)
  • Table 55. Asia Pacific Cancer Profiling, by Type USD Million (2017-2022)
  • Table 56. Asia Pacific Cancer Profiling, by Application USD Million (2017-2022)
  • Table 57. Asia Pacific Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 58. Asia Pacific Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 59. Asia Pacific Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 60. China Cancer Profiling, by Type USD Million (2017-2022)
  • Table 61. China Cancer Profiling, by Application USD Million (2017-2022)
  • Table 62. China Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 63. China Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 64. China Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 65. Japan Cancer Profiling, by Type USD Million (2017-2022)
  • Table 66. Japan Cancer Profiling, by Application USD Million (2017-2022)
  • Table 67. Japan Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 68. Japan Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 69. Japan Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 70. India Cancer Profiling, by Type USD Million (2017-2022)
  • Table 71. India Cancer Profiling, by Application USD Million (2017-2022)
  • Table 72. India Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 73. India Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 74. India Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 75. South Korea Cancer Profiling, by Type USD Million (2017-2022)
  • Table 76. South Korea Cancer Profiling, by Application USD Million (2017-2022)
  • Table 77. South Korea Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 78. South Korea Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 79. South Korea Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 80. Taiwan Cancer Profiling, by Type USD Million (2017-2022)
  • Table 81. Taiwan Cancer Profiling, by Application USD Million (2017-2022)
  • Table 82. Taiwan Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 83. Taiwan Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 84. Taiwan Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 85. Australia Cancer Profiling, by Type USD Million (2017-2022)
  • Table 86. Australia Cancer Profiling, by Application USD Million (2017-2022)
  • Table 87. Australia Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 88. Australia Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 89. Australia Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 90. Rest of Asia-Pacific Cancer Profiling, by Type USD Million (2017-2022)
  • Table 91. Rest of Asia-Pacific Cancer Profiling, by Application USD Million (2017-2022)
  • Table 92. Rest of Asia-Pacific Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 93. Rest of Asia-Pacific Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 94. Rest of Asia-Pacific Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 95. Europe Cancer Profiling, by Country USD Million (2017-2022)
  • Table 96. Europe Cancer Profiling, by Type USD Million (2017-2022)
  • Table 97. Europe Cancer Profiling, by Application USD Million (2017-2022)
  • Table 98. Europe Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 99. Europe Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 100. Europe Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 101. Germany Cancer Profiling, by Type USD Million (2017-2022)
  • Table 102. Germany Cancer Profiling, by Application USD Million (2017-2022)
  • Table 103. Germany Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 104. Germany Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 105. Germany Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 106. France Cancer Profiling, by Type USD Million (2017-2022)
  • Table 107. France Cancer Profiling, by Application USD Million (2017-2022)
  • Table 108. France Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 109. France Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 110. France Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 111. Italy Cancer Profiling, by Type USD Million (2017-2022)
  • Table 112. Italy Cancer Profiling, by Application USD Million (2017-2022)
  • Table 113. Italy Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 114. Italy Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 115. Italy Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 116. United Kingdom Cancer Profiling, by Type USD Million (2017-2022)
  • Table 117. United Kingdom Cancer Profiling, by Application USD Million (2017-2022)
  • Table 118. United Kingdom Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 119. United Kingdom Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 120. United Kingdom Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 121. Netherlands Cancer Profiling, by Type USD Million (2017-2022)
  • Table 122. Netherlands Cancer Profiling, by Application USD Million (2017-2022)
  • Table 123. Netherlands Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 124. Netherlands Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 125. Netherlands Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 126. Rest of Europe Cancer Profiling, by Type USD Million (2017-2022)
  • Table 127. Rest of Europe Cancer Profiling, by Application USD Million (2017-2022)
  • Table 128. Rest of Europe Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 129. Rest of Europe Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 130. Rest of Europe Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 131. MEA Cancer Profiling, by Country USD Million (2017-2022)
  • Table 132. MEA Cancer Profiling, by Type USD Million (2017-2022)
  • Table 133. MEA Cancer Profiling, by Application USD Million (2017-2022)
  • Table 134. MEA Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 135. MEA Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 136. MEA Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 137. Middle East Cancer Profiling, by Type USD Million (2017-2022)
  • Table 138. Middle East Cancer Profiling, by Application USD Million (2017-2022)
  • Table 139. Middle East Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 140. Middle East Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 141. Middle East Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 142. Africa Cancer Profiling, by Type USD Million (2017-2022)
  • Table 143. Africa Cancer Profiling, by Application USD Million (2017-2022)
  • Table 144. Africa Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 145. Africa Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 146. Africa Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 147. North America Cancer Profiling, by Country USD Million (2017-2022)
  • Table 148. North America Cancer Profiling, by Type USD Million (2017-2022)
  • Table 149. North America Cancer Profiling, by Application USD Million (2017-2022)
  • Table 150. North America Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 151. North America Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 152. North America Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 153. United States Cancer Profiling, by Type USD Million (2017-2022)
  • Table 154. United States Cancer Profiling, by Application USD Million (2017-2022)
  • Table 155. United States Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 156. United States Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 157. United States Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 158. Canada Cancer Profiling, by Type USD Million (2017-2022)
  • Table 159. Canada Cancer Profiling, by Application USD Million (2017-2022)
  • Table 160. Canada Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 161. Canada Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 162. Canada Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 163. Mexico Cancer Profiling, by Type USD Million (2017-2022)
  • Table 164. Mexico Cancer Profiling, by Application USD Million (2017-2022)
  • Table 165. Mexico Cancer Profiling, by Treatment USD Million (2017-2022)
  • Table 166. Mexico Cancer Profiling, by Technology USD Million (2017-2022)
  • Table 167. Mexico Cancer Profiling, by Technique USD Million (2017-2022)
  • Table 168. Cancer Profiling: by Type(USD/Units)
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Company Basic Information, Sales Area and Its Competitors
  • Table 176. Company Basic Information, Sales Area and Its Competitors
  • Table 177. Company Basic Information, Sales Area and Its Competitors
  • Table 178. Company Basic Information, Sales Area and Its Competitors
  • Table 179. Company Basic Information, Sales Area and Its Competitors
  • Table 180. Cancer Profiling: by Type(USD Million)
  • Table 181. Cancer Profiling Breast Cancer , by Region USD Million (2023-2028)
  • Table 182. Cancer Profiling Lung Cancer , by Region USD Million (2023-2028)
  • Table 183. Cancer Profiling Prostate Cancer , by Region USD Million (2023-2028)
  • Table 184. Cancer Profiling Thyroid Cancer , by Region USD Million (2023-2028)
  • Table 185. Cancer Profiling Kidney Cancer , by Region USD Million (2023-2028)
  • Table 186. Cancer Profiling Others [Melanoma, Colorectal, Bladder, Leukemia] , by Region USD Million (2023-2028)
  • Table 187. Cancer Profiling: by Application(USD Million)
  • Table 188. Cancer Profiling Clinical , by Region USD Million (2023-2028)
  • Table 189. Cancer Profiling Screening , by Region USD Million (2023-2028)
  • Table 190. Cancer Profiling Research , by Region USD Million (2023-2028)
  • Table 191. Cancer Profiling: by Treatment(USD Million)
  • Table 192. Cancer Profiling Surgery , by Region USD Million (2023-2028)
  • Table 193. Cancer Profiling Radiation Therapy , by Region USD Million (2023-2028)
  • Table 194. Cancer Profiling Chemotherapy , by Region USD Million (2023-2028)
  • Table 195. Cancer Profiling Immunotherapy , by Region USD Million (2023-2028)
  • Table 196. Cancer Profiling Targeted Therapy , by Region USD Million (2023-2028)
  • Table 197. Cancer Profiling Hormone Therapy , by Region USD Million (2023-2028)
  • Table 198. Cancer Profiling Stem Cell Transplant , by Region USD Million (2023-2028)
  • Table 199. Cancer Profiling Precision Medicine , by Region USD Million (2023-2028)
  • Table 200. Cancer Profiling: by Technology(USD Million)
  • Table 201. Cancer Profiling Next-Generation Sequencing (NGS) , by Region USD Million (2023-2028)
  • Table 202. Cancer Profiling Sanger Sequencing , by Region USD Million (2023-2028)
  • Table 203. Cancer Profiling Immunohistochemistry (IHC) , by Region USD Million (2023-2028)
  • Table 204. Cancer Profiling In Situ Hybridization (ISH) , by Region USD Million (2023-2028)
  • Table 205. Cancer Profiling Microarray , by Region USD Million (2023-2028)
  • Table 206. Cancer Profiling Others , by Region USD Million (2023-2028)
  • Table 207. Cancer Profiling: by Technique(USD Million)
  • Table 208. Cancer Profiling Genomics , by Region USD Million (2023-2028)
  • Table 209. Cancer Profiling Proteomics , by Region USD Million (2023-2028)
  • Table 210. Cancer Profiling Epigenetics , by Region USD Million (2023-2028)
  • Table 211. Cancer Profiling Metabolomics , by Region USD Million (2023-2028)
  • Table 212. South America Cancer Profiling, by Country USD Million (2023-2028)
  • Table 213. South America Cancer Profiling, by Type USD Million (2023-2028)
  • Table 214. South America Cancer Profiling, by Application USD Million (2023-2028)
  • Table 215. South America Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 216. South America Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 217. South America Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 218. Brazil Cancer Profiling, by Type USD Million (2023-2028)
  • Table 219. Brazil Cancer Profiling, by Application USD Million (2023-2028)
  • Table 220. Brazil Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 221. Brazil Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 222. Brazil Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 223. Argentina Cancer Profiling, by Type USD Million (2023-2028)
  • Table 224. Argentina Cancer Profiling, by Application USD Million (2023-2028)
  • Table 225. Argentina Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 226. Argentina Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 227. Argentina Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 228. Rest of South America Cancer Profiling, by Type USD Million (2023-2028)
  • Table 229. Rest of South America Cancer Profiling, by Application USD Million (2023-2028)
  • Table 230. Rest of South America Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 231. Rest of South America Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 232. Rest of South America Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 233. Asia Pacific Cancer Profiling, by Country USD Million (2023-2028)
  • Table 234. Asia Pacific Cancer Profiling, by Type USD Million (2023-2028)
  • Table 235. Asia Pacific Cancer Profiling, by Application USD Million (2023-2028)
  • Table 236. Asia Pacific Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 237. Asia Pacific Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 238. Asia Pacific Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 239. China Cancer Profiling, by Type USD Million (2023-2028)
  • Table 240. China Cancer Profiling, by Application USD Million (2023-2028)
  • Table 241. China Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 242. China Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 243. China Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 244. Japan Cancer Profiling, by Type USD Million (2023-2028)
  • Table 245. Japan Cancer Profiling, by Application USD Million (2023-2028)
  • Table 246. Japan Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 247. Japan Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 248. Japan Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 249. India Cancer Profiling, by Type USD Million (2023-2028)
  • Table 250. India Cancer Profiling, by Application USD Million (2023-2028)
  • Table 251. India Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 252. India Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 253. India Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 254. South Korea Cancer Profiling, by Type USD Million (2023-2028)
  • Table 255. South Korea Cancer Profiling, by Application USD Million (2023-2028)
  • Table 256. South Korea Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 257. South Korea Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 258. South Korea Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 259. Taiwan Cancer Profiling, by Type USD Million (2023-2028)
  • Table 260. Taiwan Cancer Profiling, by Application USD Million (2023-2028)
  • Table 261. Taiwan Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 262. Taiwan Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 263. Taiwan Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 264. Australia Cancer Profiling, by Type USD Million (2023-2028)
  • Table 265. Australia Cancer Profiling, by Application USD Million (2023-2028)
  • Table 266. Australia Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 267. Australia Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 268. Australia Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 269. Rest of Asia-Pacific Cancer Profiling, by Type USD Million (2023-2028)
  • Table 270. Rest of Asia-Pacific Cancer Profiling, by Application USD Million (2023-2028)
  • Table 271. Rest of Asia-Pacific Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 272. Rest of Asia-Pacific Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 273. Rest of Asia-Pacific Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 274. Europe Cancer Profiling, by Country USD Million (2023-2028)
  • Table 275. Europe Cancer Profiling, by Type USD Million (2023-2028)
  • Table 276. Europe Cancer Profiling, by Application USD Million (2023-2028)
  • Table 277. Europe Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 278. Europe Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 279. Europe Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 280. Germany Cancer Profiling, by Type USD Million (2023-2028)
  • Table 281. Germany Cancer Profiling, by Application USD Million (2023-2028)
  • Table 282. Germany Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 283. Germany Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 284. Germany Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 285. France Cancer Profiling, by Type USD Million (2023-2028)
  • Table 286. France Cancer Profiling, by Application USD Million (2023-2028)
  • Table 287. France Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 288. France Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 289. France Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 290. Italy Cancer Profiling, by Type USD Million (2023-2028)
  • Table 291. Italy Cancer Profiling, by Application USD Million (2023-2028)
  • Table 292. Italy Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 293. Italy Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 294. Italy Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 295. United Kingdom Cancer Profiling, by Type USD Million (2023-2028)
  • Table 296. United Kingdom Cancer Profiling, by Application USD Million (2023-2028)
  • Table 297. United Kingdom Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 298. United Kingdom Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 299. United Kingdom Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 300. Netherlands Cancer Profiling, by Type USD Million (2023-2028)
  • Table 301. Netherlands Cancer Profiling, by Application USD Million (2023-2028)
  • Table 302. Netherlands Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 303. Netherlands Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 304. Netherlands Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 305. Rest of Europe Cancer Profiling, by Type USD Million (2023-2028)
  • Table 306. Rest of Europe Cancer Profiling, by Application USD Million (2023-2028)
  • Table 307. Rest of Europe Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 308. Rest of Europe Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 309. Rest of Europe Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 310. MEA Cancer Profiling, by Country USD Million (2023-2028)
  • Table 311. MEA Cancer Profiling, by Type USD Million (2023-2028)
  • Table 312. MEA Cancer Profiling, by Application USD Million (2023-2028)
  • Table 313. MEA Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 314. MEA Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 315. MEA Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 316. Middle East Cancer Profiling, by Type USD Million (2023-2028)
  • Table 317. Middle East Cancer Profiling, by Application USD Million (2023-2028)
  • Table 318. Middle East Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 319. Middle East Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 320. Middle East Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 321. Africa Cancer Profiling, by Type USD Million (2023-2028)
  • Table 322. Africa Cancer Profiling, by Application USD Million (2023-2028)
  • Table 323. Africa Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 324. Africa Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 325. Africa Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 326. North America Cancer Profiling, by Country USD Million (2023-2028)
  • Table 327. North America Cancer Profiling, by Type USD Million (2023-2028)
  • Table 328. North America Cancer Profiling, by Application USD Million (2023-2028)
  • Table 329. North America Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 330. North America Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 331. North America Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 332. United States Cancer Profiling, by Type USD Million (2023-2028)
  • Table 333. United States Cancer Profiling, by Application USD Million (2023-2028)
  • Table 334. United States Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 335. United States Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 336. United States Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 337. Canada Cancer Profiling, by Type USD Million (2023-2028)
  • Table 338. Canada Cancer Profiling, by Application USD Million (2023-2028)
  • Table 339. Canada Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 340. Canada Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 341. Canada Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 342. Mexico Cancer Profiling, by Type USD Million (2023-2028)
  • Table 343. Mexico Cancer Profiling, by Application USD Million (2023-2028)
  • Table 344. Mexico Cancer Profiling, by Treatment USD Million (2023-2028)
  • Table 345. Mexico Cancer Profiling, by Technology USD Million (2023-2028)
  • Table 346. Mexico Cancer Profiling, by Technique USD Million (2023-2028)
  • Table 347. Cancer Profiling: by Type(USD/Units)
  • Table 348. Research Programs/Design for This Report
  • Table 349. Key Data Information from Secondary Sources
  • Table 350. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Profiling: by Type USD Million (2017-2022)
  • Figure 5. Global Cancer Profiling: by Application USD Million (2017-2022)
  • Figure 6. Global Cancer Profiling: by Treatment USD Million (2017-2022)
  • Figure 7. Global Cancer Profiling: by Technology USD Million (2017-2022)
  • Figure 8. Global Cancer Profiling: by Technique USD Million (2017-2022)
  • Figure 9. South America Cancer Profiling Share (%), by Country
  • Figure 10. Asia Pacific Cancer Profiling Share (%), by Country
  • Figure 11. Europe Cancer Profiling Share (%), by Country
  • Figure 12. MEA Cancer Profiling Share (%), by Country
  • Figure 13. North America Cancer Profiling Share (%), by Country
  • Figure 14. Global Cancer Profiling: by Type USD/Units (2017-2022)
  • Figure 15. Global Cancer Profiling share by Players 2022 (%)
  • Figure 16. Global Cancer Profiling share by Players (Top 3) 2022(%)
  • Figure 17. Global Cancer Profiling share by Players (Top 5) 2022(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Qiagen (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Qiagen (Germany) Revenue: by Geography 2022
  • Figure 21. Neogenomics Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Neogenomics Laboratories Inc. (United States) Revenue: by Geography 2022
  • Figure 23. HTG Molecular Diagnostics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. HTG Molecular Diagnostics Inc. (United States) Revenue: by Geography 2022
  • Figure 25. Perthera, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Perthera, Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Strand Genomics (India) Revenue, Net Income and Gross profit
  • Figure 28. Strand Genomics (India) Revenue: by Geography 2022
  • Figure 29. Contextual Genomics (Canada) Revenue, Net Income and Gross profit
  • Figure 30. Contextual Genomics (Canada) Revenue: by Geography 2022
  • Figure 31. QIAGEN N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 32. QIAGEN N.V. (Germany) Revenue: by Geography 2022
  • Figure 33. Boreal Genomics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Boreal Genomics (United States) Revenue: by Geography 2022
  • Figure 35. Oxford Gene Technology Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. Oxford Gene Technology Ltd (United Kingdom) Revenue: by Geography 2022
  • Figure 37. GenomeDx (Canada) Revenue, Net Income and Gross profit
  • Figure 38. GenomeDx (Canada) Revenue: by Geography 2022
  • Figure 39. Foundation Medicine Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Foundation Medicine Inc. (United States) Revenue: by Geography 2022
  • Figure 41. Global Cancer Profiling: by Type USD Million (2023-2028)
  • Figure 42. Global Cancer Profiling: by Application USD Million (2023-2028)
  • Figure 43. Global Cancer Profiling: by Treatment USD Million (2023-2028)
  • Figure 44. Global Cancer Profiling: by Technology USD Million (2023-2028)
  • Figure 45. Global Cancer Profiling: by Technique USD Million (2023-2028)
  • Figure 46. South America Cancer Profiling Share (%), by Country
  • Figure 47. Asia Pacific Cancer Profiling Share (%), by Country
  • Figure 48. Europe Cancer Profiling Share (%), by Country
  • Figure 49. MEA Cancer Profiling Share (%), by Country
  • Figure 50. North America Cancer Profiling Share (%), by Country
  • Figure 51. Global Cancer Profiling: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Qiagen (Germany)
  • Neogenomics Laboratories Inc. (United States)
  • HTG Molecular Diagnostics Inc. (United States)
  • Perthera, Inc. (United States)
  • Strand Genomics (India)
  • Contextual Genomics (Canada)
  • QIAGEN N.V. (Germany)
  • Boreal Genomics (United States)
  • Oxford Gene Technology Ltd (United Kingdom)
  • GenomeDx (Canada)
  • Foundation Medicine Inc. (United States)
Additional players considered in the study are as follows:
Helomics Corp (United States) , Siemens Healthcare GmbH (Germany) , F. Hoffmann-La Roche Ltd (Switzerland) , NanoString Technologies Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2023 211 Pages 85 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Profiling Market Quantitative research analysis
Global Cancer Profiling Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Cancer Profiling market are Qiagen (Germany), Neogenomics Laboratories Inc. (United States), HTG Molecular Diagnostics Inc. (United States), Perthera, Inc. (United States), Strand Genomics (India), Contextual Genomics (Canada), QIAGEN N.V. (Germany), Boreal Genomics (United States), Oxford Gene Technology Ltd (United Kingdom), GenomeDx (Canada) and Foundation Medicine Inc. (United States).
In this highly competitive & fast evolving Cancer Profiling industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Clinical, Screening and Research are the potential customers of Cancer Profiling industry.

Know More About Global Cancer Profiling Market Report?

Have a Query? Click Here

Other Related Reports

Multipurpose Systems Comprehensive Study by Application (Ambulance, RHC, Home care, Intensive care room), Components (Hardware, Software), Modules (Biosignal acquisition module, Digital camera, Proce...
$ 3450
Fertility Services Comprehensive Study by Application (Fertility clinics, Hospitals, Surgical centers, Clinical Research Institutes), Treatment (Assistive reproductive technology (ART) (Artificial in...
$ 3750
Healthcare Interoperability Solutions Comprehensive Study by Type (Software Solutions {EMR/EHR, Lab Systems, Imaging Systems, Healthcare Information Exchange, Enterprise, Other(Medical Billing, Pract...
$ 3750
Dental Restorative Comprehensive Study by Type (Dental amalgams, Dental cements, Dental composites, Dental ceramics, Dental liners), Application (Prosthodontics, Periodontics,, Periodontics), End Use...
$ 3450
Lung Transplant Rejection Comprehensive Study by Type (Cellular Rejection, Antibody-Mediated Rejections, Allograft Rejection, Acute Rejections, Chronic Rejections), Application (Lung Transplant Patie...
$ 3500
Interventional Pulmonology Comprehensive Study by Type (Bronchoscopes, Electromagnetic Navigation Bronchoscopy Systems, Pleuroscopes, Respiratory Endotherapy Devices, Airway Stents, Pleural Catheters...
$ 3750